Migraine Amgen
Aug 08, 2018
Snippet : Migraine
Teva’s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical’s fremanezumab for treating migraine is expected to launch later this year. Celltrion disclosed that U.S. drug regulators issued a Form 483 for its plant in Incheon, South Korea on tuesdsy. Eight manufacturin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
